Skip to main content
. 2021 Nov 24;18(23):12325. doi: 10.3390/ijerph182312325

Table 1.

Sample characteristics.

Time 1
(n = 146)
Time 2
(n = 58)
Age (years), mean (SD; min–max) 68 (9.6; 35–80) 69 (8.9; 46–84)
Female gender, n (%) 67 (46) 32 (55)
PD duration (years), mean (SD; min–max) 4.0 (3.9; 0.1–17.0) 7.0 (3.7; 3.6–20)
PD severity (HY), median (q1–q3; min–max) 2 (2–3; 1–4) 2 (2–3; 1–4)
Daily total levodopa equivalent (LDE) dose (mg), median (q1–q3; min–max) 400 (300−600; 0–1477) 500 (400–675; 150–1580)
Self-rated motor status at the time of clinical examination
“on” or “on with dyskinesias,” n (%)
“off,” n (%)

128 (88)
18 (12)

48 (83)
10 (17)
Motor symptoms (UPDRS part III), median (q1–q3; min–max) 12 (8–18; 1–46) 13.5 (9–20; 1–40)
Cognition (MMSE), median (q1–q3; min–max) 28 (26–29; 19–30) 28 (27–29; 20–30)
Retropulsion (NRT), median (q1–q3; min–max) 0 (0–1; 0–2) 0 (0–1; 0–3)
Retropulsion (UPDRS30), median (q1–q3; min–max) 0 (0–1; 0–2) 0 (0–1; 0–3)

HY, Hoehn and Yahr; MMSE, Mini-Mental State Examination; NRT, Nutt Retropulsion Test; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease; Rating Scale; UPDRS part III, motor score of the Unified Parkinson’s Disease Rating Scale; UPDRS30, item 30 of UPDRS.